Tests progesterone to see whether it prevents preeclampsia in pregnancy
Tests vaginal progesterone in low-risk pregnant adults to study preeclampsia.
Plain-language title generated from the registry record
Registry title: Progesterone Preeclampsia
Key facts
- Where
- Charleston, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Medical University of South CarolinaCharleston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of South Carolina
- Trial code
- NCT07448597
- Record updated
- 17 August 2026
- Original description
This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.Read full original descriptionShow less
Progesterone Supplementation for the Prevention of Preeclampsia
This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.
Inclusion: Pregnant individuals receiving prenatal care at participating clinics; <12 weeks gestation with a viable intrauterine pregnancy; Age ≥18 years; English-speaking.
Exclusion: Unable or unwilling to self-administer vaginal progesterone; Inability or unwillingness to provide informed consent.